2023 World Conference on Lung Cancer (Posters)-EP03.03. Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer

EP03.03. Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer - PDF(Abstract)

Pdf Summary

This abstract presents the results of a study analyzing the impact of mutations in the STK11 gene on the tumor immune microenvironment (TME) in non-small cell lung cancer (NSCLC). The researchers utilized data from The Cancer Genomic Atlas (TCGA) to analyze the association between STK11 mutations and immune cell infiltration in NSCLC tumors. They found that STK11 mutations were more common in lung adenocarcinoma (LUAD) patients compared to squamous cell carcinoma (LUSC) patients. KRAS and KEAP1 were the most common mutations found in STK11-mutated tumors. STK11 mutations were significantly associated with poorer overall survival and progression-free survival compared to wild-type tumors. In LUAD patients, STK11 mutations were associated with lower infiltration of CD8 T-cells, CD4 T-cells, and M1 macrophages, and higher infiltration of T-regulatory cells. STK11 mutations were also associated with CTL dysfunction. Additionally, the expression of immune checkpoint genes (PD-L1, PD-1, CTLA-4, and LAG3) was higher in STK11 wild-type tumors. These findings suggest that STK11 mutations are associated with an immune-cold TME and may contribute to poor response to immunotherapy. The researchers conclude that STK11 mutations can help identify patients who are less likely to respond to immunotherapy.

Asset Subtitle

Sanad Alhushki

Meta Tag

Speaker Sanad Alhushki

Topic Tumor Biology: Translational Biology - IO

Keywords

STK11 gene

tumor immune microenvironment

non-small cell lung cancer

NSCLC

STK11 mutations

lung adenocarcinoma

squamous cell carcinoma

KRAS

KEAP1

immunotherapy